hydrea kõvakapsel
first pharma oÜ - hüdroksükarbamiid - kõvakapsel - 500mg 100tk
hydrea kõvakapsel
cheplapharm arzneimittel gmbh - hüdroksükarbamiid - kõvakapsel - 500mg 100tk
hydrea kõvakapsel
lex ano uab - hüdroksükarbamiid - kõvakapsel - 500mg 100tk
hydroxycarbamid teva kapsel
teva czech industries s.r.o. - hüdroksükarbamiid - kapsel - 500mg 100tk
siklos
theravia - hüdroksükarbamiid - aneemia, sickle cell - antineoplastilised ained - siklos on näidustatud ennetamine korduvate valus vaso-occlusive kriiside, sealhulgas ägeda rinnus sündroom lastel ja täiskasvanud patsientidel, kes põevad sümptomaatiline sirprakuline sündroom.
xromi
nova laboratories ireland limited - hüdroksükarbamiid - aneemia, sickle cell - antineoplastilised ained - ennetamine vaso-occlusive tüsistused sirprakuline patsientidel, üle 2-aastased.
adakveo
novartis europharm limited - crizanlizumab - aneemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.